Biodesix Inc (BDSX)

$1.23

-0.01

(-0.81%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Biodesix Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 9.05M → 14.66M (in $), with an average increase of 14.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -26.78M → -9.13M (in $), with an average increase of 31.6% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 16.9% return, outperforming this stock by 48.6%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 9.4% return, outperforming this stock by 103.0%

Performance

  • $1.23
    $1.26
    $1.23
    downward going graph

    0.0%

    Downside

    Day's Volatility :2.38%

    Upside

    2.38%

    downward going graph
  • $1.03
    $2.21
    $1.23
    downward going graph

    16.26%

    Downside

    52 Weeks Volatility :53.39%

    Upside

    44.34%

    downward going graph

Returns

PeriodBiodesix IncSector (Health Care)Index (Russel 2000)
3 Months
-35.26%
-1.1%
0.0%
6 Months
-25.45%
6.7%
0.0%
1 Year
-34.22%
3.2%
-0.7%
3 Years
-93.57%
15.2%
-21.6%

Highlights

Market Capitalization
116.3M
Book Value
$0.05
Earnings Per Share (EPS)
-0.64
Wall Street Target Price
3.5
Profit Margin
-106.23%
Operating Margin TTM
-46.67%
Return On Assets TTM
-26.89%
Return On Equity TTM
-414.09%
Revenue TTM
49.1M
Revenue Per Share TTM
0.6
Quarterly Revenue Growth YOY
52.7%
Gross Profit TTM
24.1M
EBITDA
-38.0M
Diluted Eps TTM
-0.64
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.42
EPS Estimate Next Year
-0.32
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Biodesix Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 184.55%

Current $1.23
Target $3.50

Company Financials

FY18Y/Y Change
Revenue
20.4M
-
Net Income
-26.2M
-
Net Profit Margin
-128.06%
-
FY19Y/Y Change
Revenue
24.6M
↑ 20.16%
Net Income
-31.4M
↑ 19.83%
Net Profit Margin
-127.71%
↑ 0.35%
FY20Y/Y Change
Revenue
45.6M
↑ 85.55%
Net Income
-36.5M
↑ 16.32%
Net Profit Margin
-80.06%
↑ 47.65%
FY21Y/Y Change
Revenue
54.5M
↑ 19.64%
Net Income
-44.5M
↑ 21.95%
Net Profit Margin
-81.61%
↓ 1.55%
FY22Y/Y Change
Revenue
38.2M
↓ 29.89%
Net Income
-80.4M
↑ 80.73%
Net Profit Margin
-210.37%
↓ 128.76%
FY23Y/Y Change
Revenue
49.1M
↑ 28.46%
Net Income
-52.1M
↓ 35.13%
Net Profit Margin
-106.23%
↑ 104.14%
Q3 FY22Q/Q Change
Revenue
11.1M
↑ 1.43%
Net Income
-16.8M
↓ 16.15%
Net Profit Margin
-151.15%
↑ 31.7%
Q4 FY22Q/Q Change
Revenue
9.6M
↓ 13.5%
Net Income
-26.8M
↑ 59.55%
Net Profit Margin
-278.79%
↓ 127.64%
Q1 FY23Q/Q Change
Revenue
9.1M
↓ 5.75%
Net Income
-17.1M
↓ 36.1%
Net Profit Margin
-189.0%
↑ 89.79%
Q2 FY23Q/Q Change
Revenue
11.9M
↑ 31.1%
Net Income
-13.4M
↓ 21.97%
Net Profit Margin
-112.5%
↑ 76.5%
Q3 FY23Q/Q Change
Revenue
13.5M
↑ 13.64%
Net Income
-10.9M
↓ 18.02%
Net Profit Margin
-81.16%
↑ 31.34%
Q4 FY23Q/Q Change
Revenue
14.7M
↑ 8.72%
Net Income
-9.1M
↓ 16.53%
Net Profit Margin
-62.31%
↑ 18.85%
FY18Y/Y Change
Total Assets
39.1M
-
Total Liabilities
237.1M
-
FY19Y/Y Change
Total Assets
41.6M
↑ 6.6%
Total Liabilities
270.2M
↑ 13.95%
FY20Y/Y Change
Total Assets
121.1M
↑ 190.8%
Total Liabilities
79.9M
↓ 70.42%
FY21Y/Y Change
Total Assets
76.1M
↓ 37.15%
Total Liabilities
56.4M
↓ 29.45%
FY22Y/Y Change
Total Assets
92.9M
↑ 22.09%
Total Liabilities
72.3M
↑ 28.26%
FY23Y/Y Change
Total Assets
99.1M
↑ 6.66%
Total Liabilities
94.5M
↑ 30.73%
Q3 FY22Q/Q Change
Total Assets
63.2M
↓ 15.99%
Total Liabilities
66.1M
↓ 2.16%
Q4 FY22Q/Q Change
Total Assets
92.9M
↑ 47.01%
Total Liabilities
72.3M
↑ 9.38%
Q1 FY23Q/Q Change
Total Assets
80.8M
↓ 13.04%
Total Liabilities
76.2M
↑ 5.45%
Q2 FY23Q/Q Change
Total Assets
77.6M
↓ 3.92%
Total Liabilities
84.6M
↑ 10.98%
Q3 FY23Q/Q Change
Total Assets
86.8M
↑ 11.8%
Total Liabilities
88.2M
↑ 4.27%
Q4 FY23Q/Q Change
Total Assets
99.1M
↑ 14.18%
Total Liabilities
94.5M
↑ 7.12%
FY18Y/Y Change
Operating Cash Flow
-17.7M
-
Investing Cash Flow
-617.0K
-
Financing Cash Flow
19.0M
-
FY19Y/Y Change
Operating Cash Flow
-21.7M
↑ 22.91%
Investing Cash Flow
-1.9M
↑ 203.4%
Financing Cash Flow
23.0M
↑ 20.7%
FY20Y/Y Change
Operating Cash Flow
-21.4M
↓ 1.66%
Investing Cash Flow
-2.9M
↑ 56.36%
Financing Cash Flow
81.1M
↑ 253.17%
FY21Y/Y Change
Operating Cash Flow
-28.2M
↑ 32.09%
Investing Cash Flow
-2.5M
↓ 12.98%
Financing Cash Flow
1.3M
↓ 98.44%
FY22Y/Y Change
Operating Cash Flow
-45.0M
↑ 59.35%
Investing Cash Flow
-3.5M
↑ 38.75%
Financing Cash Flow
58.9M
↑ 4565.77%
Q3 FY22Q/Q Change
Operating Cash Flow
-10.3M
↑ 7.68%
Investing Cash Flow
-815.0K
↑ 114.47%
Financing Cash Flow
-2.3M
↓ 110.23%
Q4 FY22Q/Q Change
Operating Cash Flow
-11.9M
↑ 15.65%
Investing Cash Flow
-2.0M
↑ 143.8%
Financing Cash Flow
41.8M
↓ 1947.59%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.7M
↓ 35.67%
Investing Cash Flow
-6.5M
↑ 225.72%
Financing Cash Flow
-2.4M
↓ 105.79%
Q2 FY23Q/Q Change
Operating Cash Flow
937.0K
↓ 112.19%
Investing Cash Flow
-6.5M
↑ 0.0%
Financing Cash Flow
-2.3M
↓ 3.76%

Technicals Summary

Sell

Neutral

Buy

Biodesix Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biodesix Inc
Biodesix Inc
-16.33%
-25.45%
-34.22%
-93.57%
-90.4%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-6.04%
15.89%
3.38%
-5.8%
121.02%
Agilent Technologies Inc.
Agilent Technologies Inc.
-4.58%
26.22%
0.39%
5.59%
75.04%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-3.24%
15.7%
-3.97%
14.33%
103.64%
Danaher Corp.
Danaher Corp.
-3.79%
14.02%
-6.18%
-1.09%
83.87%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-7.31%
17.72%
15.6%
9.39%
66.03%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biodesix Inc
Biodesix Inc
NA
NA
NA
-0.42
-4.14
-0.27
NA
0.05
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
50.21
50.21
4.81
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
34.49
34.49
2.77
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.18
37.18
2.85
21.56
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
43.44
43.44
3.2
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.8
32.8
1.4
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biodesix Inc
Biodesix Inc
Buy
$116.3M
-90.4%
NA
-106.23%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.9B
121.02%
50.21
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$42.2B
75.04%
34.49
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.0B
103.64%
37.18
13.99%
Danaher Corp.
Danaher Corp.
Buy
$182.1B
83.87%
43.44
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$43.6B
66.03%
32.8
9.06%

Institutional Holdings

  • Birchview Capital, LP

    5.36%
  • AIGH Capital Management, LLC

    4.81%
  • Worth Venture Partners, LLC

    1.18%
  • Essex Investment Management Company, LLC

    0.94%
  • Wells Fargo & Co

    0.91%
  • Vanguard Group Inc

    0.84%

Corporate Announcements

  • Biodesix Inc Earnings

    Biodesix Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

biodesix develops and commercializes blood-based molecular diagnostic tests that advance the standard of care in oncology. our diagnostics help patients and their doctors make more informed decisions about treatment based on a patient's unique molecular profile. we're advancing precision medicine by helping physicians provide the right patient with the right treatment at the right time, and move patients to optimal treatment faster. we partner with pharmaceutical companies to develop tests that accelerate pipelines and bring effective therapies to market. our two commercialized tests, veristrat® & genestrat™, offer results in 72 hours. no tissue is required.

Organization
Biodesix Inc
Employees
217
CEO
Mr. Scott Hutton
Industry
Health Services

FAQs